Led · Series B · Jan 2026

Founded in 2010 and headquartered in Cleveland, Ohio, Enspire DBS Therapy is building a first-in-class neuromodulation solution that pairs deep brain stimulation (DBS) with structured rehabilitation to restore upper-extremity function after stroke. Its lead program is being evaluated in the multicenter RESTORE pivotal clinical trial, which implants a commercially available third-party DBS system and compares DBS + Rehab to rehabilitation alone in patients with chronic arm impairment. The study is being conducted under an FDA Investigational Device Exemption and is targeting long-term safety and effectiveness data needed for future U.S. marketing authorization, with interim results expected in mid-2027. Proceeds from recent funding will accelerate patient enrollment and trial execution. Financially, the company remains pre-commercial and recently secured $10.3 million in fresh capital, bringing additional institutional support and board expertise. Existing backers Cleveland Clinic and JobsOhio Ventures have recommitted to the venture alongside new lead investor Genesys Capital. Enspire aims to translate breakthrough neuroscience into clinically meaningful outcomes for the roughly 800,000 Americans who suffer a stroke each year.

Participated · Series C · Mar 2024

Flosonics Medical is a Canadian medical device company (founded 2015, Sudbury, Ontario) that develops FloPatch, a wireless wearable Doppler ultrasound designed to deliver rapid, repeatable hemodynamic assessments at the bedside. FloPatch aims to help clinicians assess fluid responsiveness and streamline critical decisions in sepsis and other acute-care settings, reducing fluid-related complications and improving patient outcomes. The company positions the device as a faster, more accessible alternative to traditional Doppler ultrasound machines in emergency and intensive care environments. Flosonics says the funding will accelerate market adoption and enable broader hospital deployment across North America and beyond. The announcement highlights the company’s focus on non-invasive, data-driven solutions and ongoing clinical research to support its technology. Financially, Flosonics secured venture debt to support scaling operations and commercialization efforts. Flosonics Medical develops FloPatch, a first-in-class wearable Doppler ultrasound designed for hemodynamic assessments. The device is intended to improve management of critically ill patients and support monitoring both inside and outside the hospital. The company emphasizes continued evidence generation to validate clinical use. Flosonics plans to expand indications for use and accelerate commercial growth and market adoption. The firm is a Canadian medical device company based in Sudbury, Ontario, founded in 2015. Recent financing will be used to support innovation, expansion, and broader deployment of its wearable AI-assisted sensor technology. Flosonics Medical is a venture-backed medical device company developing the FloPatch, a low-cost, wearable Doppler ultrasound sensor that adheres to a patient’s neck and sends hands-free blood flow data wirelessly via low-energy Bluetooth. The company says FloPatch enables on-demand, non-invasive Doppler measurement of blood flow to support management of critically ill patients across emergency, OR, ward, and ICU settings. Its first product, the FloPatch FP 120, has received regulatory clearances from the FDA and Health Canada. Founded in 2015 and headquartered in Sudbury, Ontario, Flosonics employs over 20 people focused on R&D. Financing proceeds will be used for a commercial launch in North America and for new product development as the technology transitions to clinical use.

Participated · Equity · Jun 2023

Veralox Therapeutics is a clinical-stage biotechnology company developing first-in-class therapeutics that target the 12-lipoxygenase (12-LOX) pathway. Its lead candidate, VLX-1005, is in development for heparin-induced thrombocytopenia (HIT) and has U.S. orphan drug designation and FDA Fast Track designation. The company is preparing a Phase 2a proof-of-concept study in HIT and is also developing second-generation products for type 1 diabetes and other immune-mediated and inflammatory diseases. In June 2023 Veralox announced a $24 million financing that the company said fully funds the Phase 2a clinical program for VLX-1005. In conjunction with the financing the company named Jonathan Mow as CEO and added Peter Young of Pappas Capital to its board, with Meg Wood of NYBC Ventures joining as an observer. Veralox is based in Frederick, Maryland. Veralox Therapeutics is a biotechnology company developing small-molecule therapeutics to treat the underlying causes of diseases with significant unmet medical needs. The company is led by University of Maryland graduate Jeffrey Strovel, PhD, who serves as chief executive officer. Veralox announced the closing of a $16 million Series A financing in June 2021. Investors in the round include Sanofi Ventures, Genesys Capital, Hatteras Venture Partners, JDRF T1D Fund, Point Field Partners, VTC Innovation Fund, the University System of Maryland Momentum Fund, and TEDCO. Veralox was an early portfolio company of the USM Momentum Fund, which made a $500,000 seed investment in 2019. The Momentum Fund has also provided connections to potential partners and strategic counsel, which the company cites as contributing to its growth. Veralox Therapeutics is a preclinical-stage biopharma company focused on developing first-in-class inhibitors of 12‑LOX, an enzyme implicated in platelet activation and cellular stress signaling. Its lead candidate, VLX-1005, was discovered and developed in collaboration with UC Santa Cruz, Thomas Jefferson University, the NIH, and Eastern Virginia Medical School. The company intends to develop VLX-1005 initially for heparin-induced thrombocytopenia and thrombosis (HITT/HIT) and is advancing second-generation products for type 1 diabetes and other immune-mediated and inflammatory diseases. The new capital will be used to support preclinical development and to prepare for clinical studies in patients. Founded in 2017 and headquartered in Maryland, Veralox was founded by Jeffrey Strovel, David Maloney, and Matthew Boxer. No revenues or operating metrics were disclosed in the announcement.

Participated · Series C · Oct 2022

Inversago Pharma is a clinical-stage biotech in Montreal focused on developing first-in-class, peripherally-acting CB1 inverse agonists. Its lead program, INV-202, is being advanced for Diabetic Kidney Disease (DKD) and is slated to enter a Phase 2 clinical trial in Q4 2022. The company announced FDA IND clearance for INV-202 and expects Phase 1b topline results in subjects with metabolic syndrome. Proceeds from the Series C will also accelerate multiple preclinical programs across its pipeline. Inversago aims to establish leadership in the field of CB1 blockade and to develop therapies for cardiometabolic, fibrotic, and other metabolic conditions. The company is privately owned and targets indications including DKD, Type 1 and Type 2 Diabetes, NASH, complications of obesity, hypertriglyceridemia, and progressive-fibrosis interstitial lung diseases. Inversago Pharma is a preclinical-stage biotech focused on first-in-class, peripherally-acting CB1 inverse agonists. Its lead candidate is INV-101 and the company plans to use recent proceeds to advance INV-101 to clinical proof-of-concept while progressing research on other selected compounds. Inversago targets metabolic and fibrotic conditions including Prader-Willi syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes and diabetic nephropathy. The company’s approach is designed to inhibit peripheral CB1 signaling—thought to be activated in many of these diseases—while avoiding the CNS liabilities associated with central CB1 blockade. Clinical and scientific data cited by the company support CB1 inhibition as an effective therapeutic strategy in several diseases, and Inversago emphasizes a safer therapeutic window through peripheral-only action. Following the financing the company expanded its board to help transition from preclinical work toward first-in-human trials. Inversago Pharma is a Montreal-based, preclinical-stage company developing new generations of peripherally-restricted CB1 inverse agonists/antagonists for Prader-Willi Syndrome, type 1 diabetes, obesity and other metabolic disorders including NASH. Its core product is a CB1 receptor blocker designed to avoid the central nervous system adverse events that terminated earlier, centrally-acting CB1 programs. The company’s technology is based on work by CB1 expert George Kunos at the NIH/NIAAA and has shown in preclinical models that peripheral CB1 blockade can treat obesity, NASH, liver fibrosis and diabetes without the behavioral CNS effects of earlier compounds. Inversago intends to advance its peripherally-restricted CB1 program into clinical trials. The company launched operations to exploit the therapeutic potential of reinstated CB1 blockade across multiple metabolic indications. The announced Series A financing will support the company’s development plan and progression toward clinical development.

Led · Seed · May 2021

Giiant Pharma is a Canadian, preclinical-stage biotech that designs gut-restricted small-molecule drug therapeutics using a proprietary Precision Delivery technology that leverages the gut microbiota to bioactivate poorly-absorbable prodrug therapeutics. Its lead program, GT-2108, is an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug intended for moderate-to-severe ulcerative colitis. The company says GT-2108 offers vastly improved drug tolerability and enhanced therapeutic effect. Giiant will use the financing to pursue an IND-enabling preclinical program for GT-2108 with the aim of an IND filing by Q2 2024. The company is currently in discussions with potential pharmaceutical partners to co-develop and accelerate the GT-2108 program. The announcement identifies the company as headquartered in Montreal. Giiant Pharma is a preclinical-stage biotech company based in Montreal that designs gut-restricted, tissue-specific small-molecule drug therapeutics using its proprietary Precision Delivery technology platform. Its lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug designed to improve drug tolerability and enhance therapeutic effect for moderate-to-severe ulcerative colitis. The company plans to use recently raised funds to initiate an IND-enabling preclinical program for GT-2108. Giiant’s pipeline targets various biological mechanisms in gastroenterology with an emphasis on localized activity in the gut. Leadership includes CEO Maxime Ranger, Chief Development Officer Dr. Elizabeth Kwong, and Chief Clinical Officer Patrick Colin. The company is positioned as a preclinical-stage therapeutics developer focused on advancing its lead candidate toward clinical entry.